[Long-term Outcomes in Eyes Receiving of Bevacizumab Early in the Course of Branch Retinal Vein Occlusion].
OBJECTIVE
To evaluate the effects of intravitreal bevacizumab (IVB) injections early in the course of branch retinal vein occlusion (BRVO).


METHODS
We conducted a retrospective review of 30 patients (30 eyes) with macular edema (ME) secondary to BRVO. The mean duration from the onset to the first IVB injection was 5 weeks. The mean observation period was 30 months. All patients were followed monthly, with administration of additional IVB injections if there was persistent or recurrent ME within 6 months after the first injection. The main outcome parameter was best-corrected visual acuity (BCVA) at 12 and 24 months. Rescue therapy including laser photocoagulation was done as needed.


RESULTS
Mean BCVA improved significantly from logMAR 0.59 ± 0.24 at baseline to 0.04 ± 0.15 (p < 0.001)at 12 month, 0.06 ± 0.19(p < 0.001)at 24 month.


CONCLUSIONS
IVB injections given shortly after onset of branch retinal vein occlusion may result in a significant increase in vision in some patients.
Masanori
M
Setta
Shiro
S
Ozaki
Akio
A
Tabuchi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000068258:Bevacizumab / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
D000068258:Bevacizumab